The latter is of particular relevance here given the physiological importance of VEGF to follicular cysts formation and the plethora of trials that have demonstrated the clinical activity of VEGF inhibitors in ovarian cancer, irrespective of the platinum/progression-free interval. This evidence concerns the gene VEGFA and Follicular Cyst.